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Introduction
Patients with advanced non-small cell lung cancer (NSCLC) often experience a high
symptom burden and a significantly deteriorated quality of life (QoL).1–3 In a realworld cross-sectional analysis of patients receiving treatment for advanced NSCLC
(N = 450), all patients reported experiencing fatigue, and most experienced loss of
appetite, shortness of breath, cough, hemoptysis, and pain.4 These data indicate that
in addition to prolonging survival, identifying a first-line treatment regimen that does
not deteriorate physical well-being but instead maintains or improves symptom burden
and/or QoL, is important for disease and treatment outcomes.
Despite recent treatment advances, chemotherapy remains the first-line standard
of care for the majority of patients with advanced NSCLC (without a high level of
PD-L1 expression), including those with squamous histology.5,6 However, there is a
paucity of longitudinal QoL data from patients with advanced NSCLC receiving chemotherapy, and the data that do exist are often contradictory. Some studies have found
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Background: Longitudinal data on the impact of treatment on quality of life (QoL) in advanced
non-small cell lung cancer (NSCLC) are limited. In this palliative setting, treatment that does
not deteriorate QoL is key. Here we report longitudinal QoL in patients with squamous NSCLC,
receiving ≤4 cycles of nab-paclitaxel/carboplatin combination chemotherapy.
Methods: Patients received nab-paclitaxel 100 mg/m2 days 1, 8, 15 + carboplatin area under
the curve 6 mg•min/mL day 1 (q3w) for four cycles. QoL was assessed by the Lung Cancer
Symptom Scale (LCSS) and Euro-QoL-5 Dimensions-5 Levels (EQ-5D-5L) at baseline and
each cycle (day 1).
Results: Two-hundred and six lesion-response-evaluable patients completed baseline + ≥1
postbaseline QoL assessment and were QoL evaluable. LCSS average total score and symptom
burden index improved from baseline throughout four cycles. In the LCSS pulmonary symptoms
score, 46% of patients reported clinically meaningful improvement (≥10 mm visual analog scale)
from baseline. Individual EQ-5D-5L dimensions remained stable/improved in ≥83% of patients;
≈33% reported complete resolution of baseline problems at least once during four cycles. Generally, responders (unconfirmed complete/partial response) had higher scores vs nonresponders.
Conclusion: In patients with squamous NSCLC, four cycles of nab-paclitaxel/carboplatin
demonstrated clinically meaningful QoL improvements, with greater benefits in responders
vs nonresponders.
Keywords: nab-paclitaxel, non-small cell lung cancer, quality of life, response, squamous
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that platinum-based chemotherapy improves QoL,7 while
others have found no improvement in QoL when compared
with other treatments such as targeted agents.8–10 Prospective QoL data from clinical trials are even more limited in
patients with squamous NSCLC, as few trials have reported
QoL outcomes by histology.
nab-Paclitaxel in combination with carboplatin is approved
for the first-line treatment of locally advanced or metastatic
NSCLC in patients who are not candidates for curative surgery
or radiation therapy, based on a favorable risk-benefit profile
compared with paclitaxel plus carboplatin in a randomized
Phase III trial.11,12 Compared with paclitaxel plus carboplatin,
nab-paclitaxel plus carboplatin demonstrated a significant
increase in the primary endpoint of overall response rate (ORR)
(33% vs 25%, P = 0.005) in the intent-to-treat population. A
subset analysis of patients with squamous histology demonstrated a 68% improvement in ORR with nab-paclitaxel plus
carboplatin compared with paclitaxel plus carboplatin (41%
vs 24%; P < 0.001).12 The nab-paclitaxel plus carboplatin regimen was also well tolerated across histologies, as evidenced
by the safety profile and patient-reported taxane-related
symptom improvements.12–14 Although significant reductions
in taxane-related symptoms such as neuropathy and neuropathic pain were reported with nab-paclitaxel plus carboplatin
compared with paclitaxel plus carboplatin, it should be noted
that improvements in these taxane-related symptoms may not
reflect improvements in overall patient QoL.14 This further
underscores the need to assess the impact of this regimen on
QoL in a prospective clinical trial.
The Phase III ABOUND.sqm trial is investigating firstline nab-paclitaxel plus carboplatin treatment followed
by nab-paclitaxel with or without best supportive care as
maintenance treatment in patients with advanced squamous
NSCLC. The objective of this analysis was to evaluate the
impact of four cycles of nab-paclitaxel plus carboplatin on
patient-reported symptoms and health-related QoL outcomes.

Ethics approval and consent to
participate
This study was conducted in accordance with the Declaration of Helsinki and Good Clinical Practice Guidelines of
the International Conference on Harmonisation. Informed
consent was obtained from all patients prior to study entry.
The study received approval from institutional review
boards prior to commencement. The trial is registered at
ClinicalTrials.gov (NCT02027428).
The approving Institutional Review Boards/Ethics Committees were Bundesinstitut für Arzneimittel und Mediz-
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inprodukte, Ethikkommission der Medizinischen Fakultät
Heidelberg, Agenzia Italiana del Farmaco, Comitato Etico
Campania Nord, Agencia Española de Medicamentos y
Productos Sanitarios (AEMPS), CEIC Hospital Clinico San
Carlos, Health Research Authority, Medicines and Healthcare
Products Regulatory Agency, NRES Committee London
Surrey Borders, and Quorum Review IRB.

Materials and methods
Study population
Patients with stage IIIB or IV, histologically or cytologically
confirmed squamous NSCLC measurable by “Response
Evaluation Criteria In Solid Tumors” (RECIST) version
1.1 were enrolled in this study. Key eligibility requirements included ≥18 years of age, no prior chemotherapy
for metastatic disease, Eastern Cooperative Oncology
Group performance status of 0 or 1, and adequate hematologic, renal, and liver function. Patients with active brain
metastases or preexisting peripheral neuropathy grade ≥2
were excluded.

Study design
The Phase III, randomized, open-label, multicenter
ABOUND.sqm study is being conducted at ≈120 sites in the
United States and the European Union. In the induction part,
patients were treated with nab-paclitaxel (ABRAXANE®,
albumin-bound paclitaxel) 100 mg/m 2 intravenously on
days 1, 8, and 15 plus carboplatin area under the curve
6 mg•min/mL intravenously on day 1, every 21 days. After
completion of four cycles, patients without progression
could continue to the maintenance part of the study in which
they would be randomized 2:1 to receive nab-paclitaxel
100 mg/m2 intravenously on days 1 and 8 every 21 days
plus best supportive care or best supportive care alone until
disease progression. Randomization was stratified by disease
stage before four cycles of treatment (IIIB vs IV), response at
randomization (complete response/partial response [CR/PR]
vs stable disease), and performance status at the end of the
induction part (0 vs 1). The primary endpoint of the study is
progression-free survival, which was measured from the time
the patient was randomized at the start of the maintenance
portion to the point of progression during the maintenance
portion. Secondary endpoints include overall survival from
randomization through the maintenance part, ORR during
the induction and maintenance parts, and disease control rate
over the entire study. Change in patient-reported QoL during the induction and maintenance parts was a prespecified
exploratory endpoint.
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QoL assessments
The Lung Cancer Symptom Scale (LCSS) and the EuroQoL-5 Dimensions-5 Levels (EQ-5D-5L) questionnaires
were used to measure QoL (Figure S1). In this analysis, per
protocol, patient-reported QoL was assessed using the LCSS
and EQ-5D-5L during four cycles of treatment on day 1 of
each cycle through the end of the induction phase (cycle 5
day 1; prior to maintenance treatment). Patients completed
the QoL self-assessments in the clinic using digital tablets.
The LCSS is a validated, disease-specific instrument
completed by both patients and observers to measure QoL
in patients with lung cancer.15 The patient version of the
LCSS consists of eight individual questions about lung
cancer symptoms (appetite, fatigue, dyspnea, cough, pain,
hemoptysis, overall symptom severity, and normal activities)
all measured during the past 24 hours, one global question
on QoL, one average total score of the nine questions, and
one mean score of the six questions on major lung cancer
symptoms. Patients answer each question using a visual analog scale (VAS) of 0 to 100 mm, where 0 = best and 100 =
worst to indicate the intensity of a symptom. Figure S1 shows
the components of the LCSS scores used in this analysis.
The EQ-5D is a generic instrument designed for selfcompletion that measures the patient’s health today and
comprises the EQ-5D and a VAS for overall QoL.16,17 The
EQ-5D includes questions on five dimensions of health
(mobility, self-care, usual activities, pain/discomfort, and
anxiety/depression). The answers to each EQ-5D-5L question are based on five qualitative levels (no problems, slight
problems, moderate problems, severe problems, or unable to
perform the activity). The EQ-5D-5L global index combines
each of the five dimensions as a measure of the patient’s
global health state. The VAS records the patient’s self-rated
status for overall QoL based on a scale of 0 to 100 where
0 = worst and 100 = best.

Lesion response evaluation
Patients had a radiographic evaluation of lesions at the end
of cycles 2 and 4. Patients with a CR or PR (by RECIST
version 1.1 during the induction phase per the investigator), or those who experienced progressive disease in either
evaluation or stable disease in both evaluations, or those who
discontinued before or by the end of cycle 4, were considered
lesion-response-evaluable.

Statistical analysis
This analysis included patients who were lesion-responseevaluable during the induction part of the study with available
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QoL data from baseline and ≥1 postbaseline visit. A clinically
meaningful improvement in LCSS or EQ-5D VAS-scaled
questions was defined as ≥1 postbaseline score for a given
time point that was ≥10 mm higher than the baseline score.3
For statistical analysis purposes, all scales were aligned so
that a positive change from baseline indicated improvement.
Changes from baseline LCSS and EQ-5D VAS-scaled items
were described by descriptive statistics. The percentages
of patients who had a clinically meaningful response, of
patients who maintained or improved from baseline in the 5
EQ-5D-5L dimensions, and of patients who had complete
resolution of a baseline problem at least once during four
cycles of treatment are summarized.

Results
Patients
Of the 540 patients planned for enrollment into the induction part of the study, 284 patients had been treated as of
September 6, 2016. Of these 284 patients, 246 patients were
lesion-response-evaluable. Of the lesion-response-evaluable
patients, the median age was 68 years, and 41% of patients
were aged ≥70 years. The majority (67%) of patients had a
baseline Eastern Cooperative Oncology Group performance
status of 1 (Table 1).

QoL compliance
Of the 284 patients treated in the induction part, 251 were
treated in cycle ≥2 and were eligible to complete ≥1 postbaseline QoL assessment. Of these, 223 (89%) completed
baseline and ≥1 postbaseline assessments.

QoL results
LCSS

In total, 206 patients were lesion-response-evaluable with
available QoL data from baseline and ≥1 postbaseline visit
and were included in the LCSS analysis. In general, symptom burden decreased and QoL improved during four cycles
of treatment with nab-paclitaxel plus carboplatin. Positive
changes from baseline were observed in several LCSS
symptom scores, including cough, appetite, and pain. For
the LCSS average total score, improvement from baseline
peaked on cycle 2 day 1 and remained stable throughout the
rest of the induction phase (Figure 1A). A similar trend was
noted for the average symptom burden index (Figure 1B).
For the lung cancer symptom score that rated the severity of
disease-specific symptoms, improvements from baseline were
observed during each of the four cycles of nab-paclitaxel plus
carboplatin treatment (Figure 1C). The changes in global
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Table 1 Selected baseline characteristics
Characteristic

Responders
(n = 124)

Nonresponders
(n = 122)

Overall
(N = 246)

Age, median years (min–max)
≥70, n (%)
≥75, n (%)
Sex, n (%)
Male
Female
Race, n (%)
White
Black or African American
Other
ECOG PS, n (%)
0
1
2

68 (43–89)
55 (44)
30 (24)

67 (43–84)
46 (38)
26 (21)

68 (43–89)
101 (41)
56 (23)

70 (56)
54 (44)

90 (74)
32 (26)

160 (65)
86 (35)

112 (90)
10 (8)
1 (1)

107 (88)
15 (12)
0 (0)

219 (89)
25 (10)
1 (<1)

39 (31)
85 (69)
0 (0)

38 (31)
81 (66)
3 (3)

77 (31)
166 (67)
3 (1)

Abbreviation: ECOG PS, Eastern Cooperative Oncology Group performance status.

score remained generally stable with respect to baseline
scores throughout the induction phase, as did the changes
in the 3-item index scores (Figure 2A and B). Overall, 46%
of patients achieved a clinically meaningful improvement
(≥10 mm) from baseline in the composite score of pulmonary
symptoms during the induction phase. Clinically meaningful
improvements in the individual items of cough, shortness of
breath, and hemoptysis were also reported in 58%, 49%, and
16% of patients, respectively.

EQ-5D-5L
Two-hundred and six patients who were lesion-responseevaluable with available QoL data from baseline and ≥1
postbaseline visit were also included in the EQ-5D-5L
analysis. The majority of patients experienced stability or
improvement from baseline in individual EQ-5D-5L items,
including self-care (91%), mobility (88%), anxiety/depression (88%), pain/discomfort (85%), and usual activities
(83%) (Table 2). In patients reporting problems at baseline,
complete resolution from baseline at least once during four
cycles of treatment was reported in 30% to 50% of patients
in individual EQ-5D-5L dimensions.

LCSS and EQ-5D-5L by lesion response
Overall, of lesion-evaluable patients who completed baseline
and ≥1 postbaseline QoL assessment, 110 were responders
(CR/PR), and 96 were nonresponders. Responders had higher
QoL scores compared with the overall population and nonresponders. LCSS average total score, average symptom burden
index, and lung cancer symptom scores were improved from
baseline in responders and were generally stable with respect
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to baseline in nonresponders (Figure 1A–C). Overall, 56% of
responders and 33% of nonresponders achieved a clinically
meaningful improvement in the composite score of pulmonary symptoms.
Across all EQ-5D-5L dimensions, stabilization or
improvements in QoL scores were more pronounced in
responders vs nonresponders and vs the overall population
(Table 2). The percentage of responders reporting complete
resolution at least once was nearly double that of nonresponders in the individual dimensions of usual activities
(39% vs 21%), pain/discomfort (44% vs 27%), and anxiety/
depression (59% vs 31%).

Discussion
These are the first published data of QoL outcomes with
nab-paclitaxel plus carboplatin treatment in patients with
advanced NSCLC. In this interim analysis of the Phase III
ABOUND.sqm trial, treatment with four cycles of first-line
nab-paclitaxel plus carboplatin resulted in maintenance of
or improvement in QoL in patients with advanced squamous
NSCLC. Clinically meaningful improvements from baseline
were observed in composite LCSS lung cancer pulmonary
symptoms in 46% of patients. In addition, several EQ5D-5L components stabilized or improved in the majority
of patients, and approximately one third of patients reported
complete resolution of a problem reported at baseline at least
once during four cycles of nab-paclitaxel plus carboplatin.
Improvement in QoL was more pronounced in responders
compared with the overall population and nonresponders.
nab-Paclitaxel plus carboplatin is a recommended regimen for the first-line treatment of patients with both squamous
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Figure 1 Lung Cancer Symptom Scale average total (A), average symptom burden index (B), and lung cancer symptom (C) scores.
Abbreviations: C, cycle; d, day.
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Figure 2 Lung Cancer Symptom Scale global (A) and 3-item index (B) scores.
Abbreviations: C, cycle; d, day.

Table 2 EQ-5D-5L maintenance/improvement and complete resolution of problems in each dimension
EQ-5D-5L
Dimension

Mobility
Self-care
Usual activities
Pain/discomfort
Anxiety/depression

Maintenance/improvement
at least once during treatment, n/N (%)

Complete resolution
at least once during treatment, n/N (%)a

Responders

Nonresponders

Overall

Responders

Nonresponders

Overall

104/110 (95)
107/110 (97)
95/110 (86)
100/110 (91)
106/110 (96)

78/96 (81)
81/96 (84)
75/96 (78)
76/96 (79)
75/96 (78)

182/206 (88)
188/206 (91)
170/206 (83)
176/206 (85)
181/206 (88)

19/52 (37)
14/24 (58)
27/70 (39)
36/82 (44)
39/66 (59)

17/51 (33)
10/24 (42)
13/63 (21)
17/63 (27)
15/49 (31)

36/103 (35)
24/48 (50)
40/133 (30)
53/145 (37)
54/115 (47)

Note: aIn patients reporting problems at baseline.
Abbreviation: EQ-5D-5L, Euro-QoL-5 Dimensions-5 Levels.

and nonsquamous advanced NSCLC, based on results of the
registrational Phase III trial vs paclitaxel plus carboplatin.5,6,12
In the Phase III registrational trial, significant improvements
in ORR were reported for nab-paclitaxel plus carboplatin vs
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paclitaxel plus carboplatin for the intent-to-treat population,
as well for the subset of patients with squamous histology.
The regimen was well tolerated with significantly less grade
≥3 neuropathy and arthralgia but more thrombocytopenia and
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anemia observed compared with paclitaxel plus carboplatin.13
Additionally, significant improvements in taxane-related
symptoms, such as neuropathy and neuropathic pain, were
reported with nab-paclitaxel plus carboplatin compared with
paclitaxel plus carboplatin, regardless of histology.14 The
improvements in QoL reported during four cycles of nabpaclitaxel plus carboplatin treatment from the ABOUND.
sqm study corroborate these findings and further expand
the understanding of the overall clinical benefit of the nabpaclitaxel plus carboplatin regimen in patients with advanced
NSCLC.12,14,18
Given the substantial symptom distress (cough, pain,
loss of appetite, and hemoptysis) associated with both lung
cancer and its treatment, QoL data are becoming an important
tool for chemotherapy decision making.19–23 The high tumor
burden in many patients with advanced NSCLC can result in
a negative impact on QoL and worsen disease-related symptoms.24,25 Patients with squamous histology represent nearly
one third of all patients with NSCLC; thus, analyses of QoL
are of great significance, as the location, size, and cavitating
nature of many squamous NSCLC tumors may increase the
symptomatic burden compared with other histologies.25–27
However, there remains a lack of prospective clinical trial
data of the impact of chemotherapy on symptoms/QoL,
particularly for platinum-doublet therapy in patient subsets
with unmet needs, such as squamous NSCLC. The current
analysis adds to the limited body of knowledge on QoL data
in patients with squamous NSCLC treated with first-line
platinum doublets, and indicates that four cycles of nabpaclitaxel plus carboplatin treatment maintain or improve
QoL in this patient population.
In addition to symptoms, patient health status (i.e., mobility, anxiety/depression, and usual activities) can be impacted
by disease and treatment. For example, in a cross-sectional
study of 126 newly diagnosed patients with advanced NSCLC
treated with docetaxel plus cisplatin, 38% reported depression
at baseline.28 QoL significantly declined with treatment in
these patients, relative to those who did not report depression
at baseline. In addition, depression was associated with worse
survival. Another study assessed QoL changes in patients
with advanced NSCLC (N = 39) and found significant
declines from baseline in physical and social functioning,
among other QoL areas, during treatment with platinumdoublet chemotherapy.29 In the current study evaluating
nab-paclitaxel plus carboplatin treatment, some health status
issues (individual EQ-5D-5L dimensions of mobility, anxiety/
depression, usual activities, pain/discomfort, and self-care)
were maintained or improved in the majority of patients, with
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≈30% reporting complete resolution from baseline at least
once during treatment.
Understanding the impact of response on QoL is also
important, as tumor shrinkage associated with tumor response
could alleviate symptoms that are related to tumor size.30,31 In
the current study, QoL improvements measured by both the
LCSS and the EQ-5D-5L were more pronounced in patients
responding (CR/PR) to nab-paclitaxel plus carboplatin during the induction phase of the study vs those not responding.
In line with these findings, in a retrospective analysis of
patient-reported health-related QoL data from a large Phase
III study in advanced NSCLC (N = 488), patients with a
CR/PR or stable disease after treatment with pemetrexed
or docetaxel demonstrated statistically significant mean
maximum improvements from baseline in all LCSS items
except for hemoptysis.30 In contrast, mean LCSS scores
for each individual item worsened for patients with disease
progression. Although the response data in this analysis are
preliminary, they provide some insight on the clinical benefit
of nab-paclitaxel plus carboplatin in patients with advanced
squamous NSCLC.
EQ-5D and LCSS are validated tools for QoL measurements, yet they both have limitations that have been discussed
at length elsewhere.15,16,32 Limitations of this analysis include
QoL assessment only during the induction phase, the homogeneous patient subset with respect to race (mostly white),
and the limited patient number in some cycles. In addition,
differences in use of supportive care for the treatment of
pain may have diluted the results of the EQ-5D-5L pain/
discomfort category. Further analyses including data from the
maintenance setting are forthcoming and may help strengthen
future QoL analyses from this study.

Conclusion
These results from the Phase III ABOUND.sqm trial demonstrate that four cycles of first-line nab-paclitaxel plus
carboplatin improved or maintained QoL in patients with
advanced squamous NSCLC. In addition, patients with a
tumor response (CR/PR) appeared to have better QoL outcomes than those without a response. These findings in conjunction with those reported from the Phase III registrational
trial support nab-paclitaxel plus carboplatin as a treatment
choice for this difficult-to-treat patient population. Moreover,
it appears that declining QoL observed in nonresponders may
be related to symptoms of disease progression. Therefore,
given the importance of response during induction therapy,
the impact of four cycles of nab-paclitaxel combination
treatment on QoL in the squamous population is promising.
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LCSS (0 to 100 mm VAS; 0 = best and 100 = worst)

Global

• 1 question: How
would you rate
your QoL today?

Average total

3-item indexa

• Appetite
• Fatigue
• Dyspnea
• Cough
• Pain
• Hemoptysis
• Lung cancer
symptoms
• Overall QoL
• Normal activity

• Lung cancer
symptoms
• Overall QoL
• Normal activity

Average symptom
burden index

• Appetite
• Fatigue
• Dyspnea
• Cough
• Pain
• Hemoptysis

Lung cancer
symptoms

• 1 question: How
bad are your
symptoms from
lung cancer?

Figure S1 Components of the LCSS used in this analysis.
Note: a The 3-item index is a sum of the listed items and is scaled from 0 to 300 mm.
Abbreviations: LCSC, Lung Cancer Symptom Scale, QoL, quality of life; VAS, visual analog scale.
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